SG11202109761TA - Hsp90-binding conjugates and formulations thereof - Google Patents
Hsp90-binding conjugates and formulations thereofInfo
- Publication number
- SG11202109761TA SG11202109761TA SG11202109761TA SG11202109761TA SG 11202109761T A SG11202109761T A SG 11202109761TA SG 11202109761T A SG11202109761T A SG 11202109761TA SG 11202109761T A SG11202109761T A SG 11202109761TA
- Authority
- SG
- Singapore
- Prior art keywords
- hsp90
- formulations
- binding conjugates
- conjugates
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828645P | 2019-04-03 | 2019-04-03 | |
US202062986245P | 2020-03-06 | 2020-03-06 | |
PCT/US2020/026137 WO2020205948A1 (en) | 2019-04-03 | 2020-04-01 | Hsp90-binding conjugates and formulations thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109761TA true SG11202109761TA (en) | 2021-10-28 |
Family
ID=72667532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109761T SG11202109761TA (en) | 2019-04-03 | 2020-04-01 | Hsp90-binding conjugates and formulations thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220184217A1 (en) |
EP (1) | EP3946320A4 (en) |
JP (1) | JP2022527821A (en) |
KR (1) | KR20210148157A (en) |
CN (1) | CN113710246A (en) |
AU (1) | AU2020253385A1 (en) |
CA (1) | CA3135174A1 (en) |
IL (1) | IL286847A (en) |
SG (1) | SG11202109761TA (en) |
TW (1) | TW202102268A (en) |
WO (1) | WO2020205948A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3094719A1 (en) * | 2018-04-05 | 2019-10-10 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
SG11202104900SA (en) | 2018-11-20 | 2021-06-29 | Univ Cornell | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
CN114790193B (en) * | 2020-12-21 | 2024-05-10 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
CN114790195B (en) * | 2020-12-21 | 2024-05-17 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
CN114790194B (en) * | 2020-12-21 | 2024-03-26 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
CN113121505B (en) * | 2021-03-02 | 2023-03-07 | 中国人民解放军海军军医大学 | Triazolone compound with antifungal and antitumor dual effects and application thereof |
WO2022235889A1 (en) * | 2021-05-05 | 2022-11-10 | Tva (Abc), Llc | Hsp90-binding conjugates and formulations thereof |
WO2024044755A2 (en) * | 2022-08-26 | 2024-02-29 | Fusion Pharmaceuticals Inc. | Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof |
WO2024212001A1 (en) * | 2023-04-14 | 2024-10-17 | Fusion Pharmaceuticals Inc. | 2,4-dihyroxy-5-isopropylphenyl derivatives and pharmaceutical compositions thereof effective as extracellular hsp90, (ehsp90)-targeted radiopharmaceuticals useful in the treatment of cancer |
WO2024211999A1 (en) * | 2023-04-14 | 2024-10-17 | Fusion Pharmaceuticals Inc. | Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555158A (en) * | 2004-11-18 | 2010-09-30 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
WO2017147240A1 (en) * | 2016-02-23 | 2017-08-31 | Tarveda Therapeutics, Inc. | Hsp90 targeted conjugates and particles and formulations thereof |
AU2018211539B2 (en) * | 2017-01-30 | 2021-10-28 | Centre National De La Recherche Scientifique | Compositions and methods for cancer imaging and radiotherapy |
CA3094719A1 (en) * | 2018-04-05 | 2019-10-10 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
-
2020
- 2020-04-01 US US17/600,692 patent/US20220184217A1/en active Pending
- 2020-04-01 AU AU2020253385A patent/AU2020253385A1/en active Pending
- 2020-04-01 CA CA3135174A patent/CA3135174A1/en active Pending
- 2020-04-01 JP JP2021559056A patent/JP2022527821A/en active Pending
- 2020-04-01 KR KR1020217031688A patent/KR20210148157A/en unknown
- 2020-04-01 WO PCT/US2020/026137 patent/WO2020205948A1/en active Application Filing
- 2020-04-01 CN CN202080027058.9A patent/CN113710246A/en active Pending
- 2020-04-01 TW TW109111249A patent/TW202102268A/en unknown
- 2020-04-01 SG SG11202109761T patent/SG11202109761TA/en unknown
- 2020-04-01 EP EP20782274.3A patent/EP3946320A4/en active Pending
-
2021
- 2021-09-30 IL IL286847A patent/IL286847A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3135174A1 (en) | 2020-10-08 |
IL286847A (en) | 2021-10-31 |
EP3946320A4 (en) | 2022-12-28 |
KR20210148157A (en) | 2021-12-07 |
AU2020253385A1 (en) | 2021-11-04 |
EP3946320A1 (en) | 2022-02-09 |
JP2022527821A (en) | 2022-06-06 |
WO2020205948A1 (en) | 2020-10-08 |
TW202102268A (en) | 2021-01-16 |
US20220184217A1 (en) | 2022-06-16 |
CN113710246A (en) | 2021-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286847A (en) | Hsp90-binding conjugates and formulations thereof | |
IL286291A (en) | Compounds and conjugates thereof | |
ZA202003833B (en) | Conjugates and preparation and use thereof | |
IL287391A (en) | Amatoxin antibody-drug conjugates and uses thereof | |
IL277791A (en) | Hsp90-targeting conjugates and formulations thereof | |
EP3554558A4 (en) | Hsp90-targeting conjugates and formulations thereof | |
IL275208A (en) | Hsp90-targeting conjugates and formulations thereof | |
IL291179A (en) | Cnp variants and conjugates thereof | |
IL290141A (en) | Anti-pvrig antibodies formulations and uses thereof | |
SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
ZA202005143B (en) | Oral formulations and uses thereof | |
IL283942A (en) | Tubulysins and protein-tubulysin conjugates | |
IL290301A (en) | Il-15 conjugates and uses thereof | |
GB201904338D0 (en) | Fluorouracil-containing formulations | |
IL291312A (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
EP3953338A4 (en) | Conjugates and their use as imaging agents | |
GB201902182D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
GB201820864D0 (en) | Antibody-drug conjugates | |
IL291543A (en) | Therapeutic formulations and uses thereof | |
IL290356A (en) | Larazotide formulations | |
IL284691A (en) | Formulations | |
EP3700533A4 (en) | Sstr-targeted conjugates and formulations thereof | |
EP3989941A4 (en) | Sstr-targeted conjugates and formulations thereof | |
EP3849546A4 (en) | Hsp90-targeting conjugates and formulations thereof | |
GB201903541D0 (en) | Compounds and conjugates |